Skip to main content
Premium Trial:

Request an Annual Quote

Sarah Cannon Cancer Institute Acquires Genospace

NEW YORK (GenomeWeb) – Hospital Corporation of America (HCA) today announced that it will acquire personalized medicine software developer Genospace.

Under the terms of the deal, Genospace will merge with HCA's Sarah Cannon cancer institute as a wholly-owned subsidiary. Financial and other terms of the agreement were not disclosed.

"As genomic information advances, it is crucial that oncologists and researchers have rapid access to an efficient and nimble technology solution for interpreting molecular data and guiding clinical decision making," Sarah Cannon Chief Medical Officer Howard Burris III said in a statement.

Genospace is developing a cloud-based platform that includes applications for data analysis, clinical trial matching, patient and physician portals, and hosting for disease-specific online communities. Sarah Cannon said it will incorporate the genomics data technology into its oncology programs in the US and the UK.

Sarah Cannon expects to complete the deal in the first quarter of fiscal year 2017. Genospace will remain headquartered in Cambridge, Massachusetts.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more